Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis

Journal article

Peer reviewed

Manuel F Rosado, Elio Donna and Yeon S Ahn

Journal of clinical oncology, Vol.21(16), pp.3171-3173

2003-08-15

PMID: 12915610

Abstract

Antineoplastic Agents - adverse effects

Humans

Middle Aged

Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy

Pyrimidines - adverse effects

Male

Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications

Lung Diseases, Interstitial - chemically induced

Benzamides

Imatinib Mesylate

Piperazines - adverse effects

20 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.1126 Chronic Myeloid Leukemia
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis
Creators: Manuel F Rosado - Sylvester Cancer Center, Miami, FL, USA
Elio Donna
Yeon S Ahn
Publication Details: Journal of clinical oncology, Vol.21(16), pp.3171-3173
Publisher: United States
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Pulmonary, Critical Care & Sleep Medicine
Language: English
Resource Type: Journal article
PMID: 12915610
Record Identifier: 991031577316502976